Most of the known mechanisms are based on the reactivation AR pathway despite a low level of blood testosterone, including AR gene mutation, emergence of AR splice variants, amplification and overexpression of the AR protein or intraprostatic production of androgens by tumor cells themselves [64]. The gene discussed is AR; the disease is neoplasm.